Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010023 · ClinicalTrials.gov registry record · Phase 1
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00010023: Completed Phase 1 study, sponsored by NYU Langone Health.
NCT00010023 is a Phase 1 study that has completed, run by NYU Langone Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00010023, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of capecitabine combined with cisplatin in treating patients who have locally advanced or metastatic solid tumors .
Interventions
- DRUG cisplatin
- DRUG capecitabine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Phase | Phase 1 |
What the finished NCT00010023 record still lists
NCT00010023 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00010023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00010023 about?
NCT00010023 is a clinical study titled "Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of capecitabine combined with cisplatin in treating patients...
What is the current status of trial NCT00010023?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-08.
What interventions are being tested in trial NCT00010023?
The interventions under investigation include: cisplatin (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00010023?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia